OPKO Health, Inc. (FRA:XCY)

Market Cap	790.58M -12.0%
Revenue (ttm)	516.88M -14.9%
Net Income	-192.21M
EPS	-0.26
Shares Out	n/a
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	n/a
Average Volume	33
Open	1.030
Previous Close	0.995
Day's Range	1.030 - 1.030
52-Week Range	0.910 - 1.299
Beta	n/a
RSI	55.66
Earnings Date	Apr 28, 2026

About OPKO Health

OPKO Health, Inc. operates as a healthcare company, in the United States, Ireland, Chile, Spain, Israel, Mexico, and internationally. The company operates in two segments, Pharmaceutical and Diagnostics. The Pharmaceutical segment develops MDX2001, a tetra-specific antibody targeting several types of solid tumors in Phase 1 clinical trials; MDX2003, a tetra-specific antibody targeting two antigens for hematological tumors in Phase 1 clinical trials; and MDX2004, a trispecific immune modulator to rebuild and sustain the patient's own immune syst...

• Industry: Medical Laboratories
• Founded: 2006
• Employees: 2,275
• Stock Exchange: Frankfurt Stock Exchange
• Ticker Symbol: XCY

Financial Performance

In 2025, OPKO Health's revenue was $606.88 million, a decrease of -14.90% compared to the previous year's $713.14 million. Losses were -$225.68 million, 324.0% more than in 2024.

Financial numbers in USD